Clinical Validation of a Cell-free DNA assay for Early Lung Cancer Detection

Memorial Sloan Kettering Radiation Oncology shared on X:

“New in Cancer Discovery from The Pike Laboratory:

Changes in genome-wide cell-free DNA reflected genomic and chromatin characteristics of lung cancer. A machine learning model identify individuals who were more or less likely to have LCSM and could save lives.”

Clinical validation of a cell-free DNA fragmentome assay for augmentation of lung cancer early detection published in Cancer Discovery

Autors: Peter J. Mazzone, Peter B. Bach, Jacob Carey, Caitlin A. Schonewolf, Katalin Bognar, Manmeet S. Ahluwalia, Marcia Cruz-Correa, David Gierada, Sonali Kotagiri, Kathryn Lloyd, Fabien Maldonado, Jesse D. Ortendahl, Lecia V. Sequist, Gerard A. Silvestri, Nichole Tanner, Jeffrey C. Thompson, Anil Vachani, Kwok-Kin Wong, Ali H. Zaidi, Joseph Catallini, Ariel Gershman, Keith Lumbard, Laurel K. Millberg, Jeff Nawrocki, Carter Portwood, Aakanksha Rangnekar, Carolina Campos. Sheridan, Niti Trivedi, Tony Wu, Yuhua Zong, Lindsey Cotton, Allison Ryan, Christopher Cisar, Alessandro Leal, Nicholas C. Dracopoli, Robert B. Scharpf, Victor E. Velculescu, Luke R. G. Pike.

Source: Memorial Sloan Kettering Radiation Oncology/X